Snowden Capital Advisors LLC Aeglea Bio Therapeutics, Inc. Transaction History

Snowden Capital Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 08, 2024	SELL	$7.02 - $9.83 $403,390 - $564,861	-57,463 Closed	0 $0
Q3 2020 Jan 08, 2024	BUY	$6.51 - $9.33 $38,363 - $54,981	5,893 Added 11.43%	57,463 $407 Million
Q1 2020 Jan 08, 2024	BUY	$3.51 - $8.48 $1,053 - $2,544	300 Added 0.59%	51,570 $240 Million
Q4 2019 Jan 30, 2024	BUY	$7.23 - $8.55 $370,682 - $438,358	51,270 New	51,270 $392 Million
Q4 2019 Jan 08, 2024	BUY	$7.23 - $8.55 $370,682 - $438,358	51,270 New	51,270 $392 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Snowden Capital Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Snowden Capital Advisors LLC with notifications on news.